Literature DB >> 30504342

Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Marc Alan Rodger1,2,3, Gregoire Le Gal1,2,3.   

Abstract

After an initial 3 to 6 months of anticoagulation for venous thromboembolism (VTE), clinicians and patients face an important question: "Do we stop anticoagulants or continue them indefinitely?" The decision is easy in some scenarios (eg, stop in VTE provoked by major surgery). In most scenarios, which are faced on a day-to-day basis in routine practice, it is a challenging decision because of uncertainty in estimates in the long-term risks (principally major bleeding) and benefits (reducing recurrent VTE) and the tight trade-offs between them. Once the decision is made to continue, the next question to tackle is "Which anticoagulant?" Here again, it is a difficult decision because of the uncertainty with regard to estimates of efficacy and the safety of anticoagulant options and the tight trade-offs between choices. We conclude with the approach that we take in our clinical practice.
© 2018 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30504342      PMCID: PMC6246028          DOI: 10.1182/asheducation-2018.1.426

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  37 in total

1.  Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.

Authors:  D W BARRITT; S C JORDAN
Journal:  Lancet       Date:  1960-06-18       Impact factor: 79.321

2.  Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.

Authors:  John Simes; Cecilia Becattini; Giancarlo Agnelli; John W Eikelboom; Adrienne C Kirby; Rebecca Mister; Paolo Prandoni; Timothy A Brighton
Journal:  Circulation       Date:  2014-08-25       Impact factor: 29.690

Review 3.  What have we learned from real-world NOAC studies in venous thromboembolism treatment?

Authors:  Jan Beyer-Westendorf
Journal:  Thromb Res       Date:  2018-02-06       Impact factor: 3.944

4.  Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Authors:  Jeffrey I Weitz; Anthonie W A Lensing; Martin H Prins; Rupert Bauersachs; Jan Beyer-Westendorf; Henri Bounameaux; Timothy A Brighton; Alexander T Cohen; Bruce L Davidson; Hervé Decousus; Maria C S Freitas; Gerlind Holberg; Ajay K Kakkar; Lloyd Haskell; Bonno van Bellen; Akos F Pap; Scott D Berkowitz; Peter Verhamme; Philip S Wells; Paolo Prandoni
Journal:  N Engl J Med       Date:  2017-03-18       Impact factor: 91.245

5.  Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment.

Authors:  Frederikus A Klok; Volker Hösel; Andreas Clemens; Wilfrid D Yollo; Clemens Tilke; Sam Schulman; Mareike Lankeit; Stavros V Konstantinides
Journal:  Eur Respir J       Date:  2016-07-28       Impact factor: 16.671

6.  Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism.

Authors:  P M Kuijer; B A Hutten; M H Prins; H R Büller
Journal:  Arch Intern Med       Date:  1999-03-08

7.  Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH).

Authors:  A Tosetto; A Iorio; M Marcucci; T Baglin; M Cushman; S Eichinger; G Palareti; D Poli; R C Tait; J Douketis
Journal:  J Thromb Haemost       Date:  2012-06       Impact factor: 5.824

8.  Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.

Authors:  Trevor Baglin; Roger Luddington; Karen Brown; Caroline Baglin
Journal:  Lancet       Date:  2003-08-16       Impact factor: 79.321

9.  Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study.

Authors:  N Riva; M Bellesini; M N D Di Minno; N Mumoli; F Pomero; M Franchini; C Fantoni; R Lupoli; B Brondi; V Borretta; C Bonfanti; W Ageno; F Dentali
Journal:  Thromb Haemost       Date:  2014-06-05       Impact factor: 5.249

Review 10.  Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.

Authors:  Lana A Castellucci; Chris Cameron; Grégoire Le Gal; Marc A Rodger; Doug Coyle; Philip S Wells; Tammy Clifford; Esteban Gandara; George Wells; Marc Carrier
Journal:  BMJ       Date:  2013-08-30
View more
  1 in total

1.  D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study.

Authors:  Gualtiero Palareti; Cristina Legnani; Emilia Antonucci; Benilde Cosmi; Daniela Poli; Sophie Testa; Alberto Tosetto; Walter Ageno; Anna Falanga; Piera Maria Ferrini; Vittorio Pengo; Paolo Prandoni
Journal:  Intern Emerg Med       Date:  2019-11-05       Impact factor: 3.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.